Table 1.

Characteristics of the included RCTs of SAMe in MDD

Author	Study typology	Duration	Dose SAMe	Administration	Primary outcome	Diagnostic criteria
Caruso 1984 [36]	SAMe vs PBO	3 weeks	200 mg/day	IM	HAM-D (21 items)	Not specified
Kagan 1990 [37]	SAMe vs PBO	3 weeks	200 mg/day	OR	HAM-D (21 items)	DSM-III
Berlanga 1992 [38]	SAMe + IMI vs PBO + IMI	2 weeks	200 mg/day	IM	HAM-D (17 items)	DSM-III-R
Papakostas 2010 [39]	SAMe + SRI vs PBO + SRI	6 weeks	800 mg/day	OR	HAM-D	DSM-IV
Delle Chiaie 2002a [40]	SAMe vs IMI	6 weeks	1600 mg/day	OR	HAM-D (21 items)	DSM-IV
Delle Chiaie 2002b [40]	SAMe vs IMI	4 weeks	400 mg/day	IM	HAM-D (21 items)	DSM-IV
Mischoulon 2014a [41]	SAMe vs PBO	12 weeks	1600–3200 mg/day	OR	HAM-D (17 items)	IDS-C ≥ 25
Mischoulon 2014b [41]	SAMe vs EST	12 weeks	1600–3200 mg/day	OR	HAM-D (17 items)	IDS-C ≥ 25
Sarris 2014a [42]	SAMe vs PBO	12 weeks	1600 mg/day	OR	HAM-D (17 items)	DSM-IV
Sarris 2014b [42]	SAMe vs EST	12 weeks	1600 mg/day	OR	HAM-D (17 items)	DSM-IV
Sarris 2018 [43]	SAMe vs PBO	8 weeks	800 mg/day	OR	MADRS	DSM-V

IM intramuscular, OR oral, PBO placebo, IMI imipramine, EST escitalopram, MDD major depressive disorder, SAMe S-Adenosylmethionine, SRI serotonin reuptake inhibitors